These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28415761)

  • 1. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.
    Yang C; Tan J; Zhu J; Wang S; Wei G
    Oncotarget; 2017 Jun; 8(23):37154-37163. PubMed ID: 28415761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LINC00460 promotes neuroblastoma tumorigenesis and cisplatin resistance by targeting miR-149-5p/DLL1 axis and activating Notch pathway in vitro and in vivo.
    Xu Y; Qiu Z; Chen J; Huang L; Zhang J; Lin J
    Drug Deliv Transl Res; 2024 Jul; 14(7):2003-2018. PubMed ID: 38161194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting mechanoregulation via FAK/YAP to overcome platinum resistance in ovarian cancer.
    Dang LN; Choi J; Lee E; Lim Y; Kwon JW; Park S
    Biomed Pharmacother; 2024 Oct; 179():117335. PubMed ID: 39191020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NUAK2 is a critical YAP target in liver cancer.
    Yuan WC; Pepe-Mooney B; Galli GG; Dill MT; Huang HT; Hao M; Wang Y; Liang H; Calogero RA; Camargo FD
    Nat Commun; 2018 Nov; 9(1):4834. PubMed ID: 30446657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Dong L; Lin F; Wu W; Liu Y; Huang W
    Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
    Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
    Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis.
    Shen S; Guo X; Yan H; Lu Y; Ji X; Li L; Liang T; Zhou D; Feng XH; Zhao JC; Yu J; Gong XG; Zhang L; Zhao B
    Cell Res; 2015 Sep; 25(9):997-1012. PubMed ID: 26272168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
    Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
    Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
    Galli GG; Carrara M; Yuan WC; Valdes-Quezada C; Gurung B; Pepe-Mooney B; Zhang T; Geeven G; Gray NS; de Laat W; Calogero RA; Camargo FD
    Mol Cell; 2015 Oct; 60(2):328-37. PubMed ID: 26439301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
    Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
    Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIP6 accelerates the proliferation and invasion of cervical cancer by upregulating oncogenic YAP signaling.
    Yang F; Li L; Zhang J; Zhang J; Yang L
    Exp Cell Res; 2020 Nov; 396(1):112248. PubMed ID: 32853630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
    Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W
    J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.
    Takemoto M; Tanaka T; Tsuji R; Togashi Y; Higashi M; Fumino S; Tajiri T
    Biochem Biophys Res Commun; 2021 Sep; 570():41-46. PubMed ID: 34271435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumine loaded smart nanoparticles through inhibition of Hippo-YAP signaling pathway.
    Sa P; Singh P; Panda S; Swain RK; Dash R; Sahoo SK
    Transl Res; 2024 Jun; 268():63-78. PubMed ID: 38499286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
    Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
    Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients.
    Xia Y; Chang T; Wang Y; Liu Y; Li W; Li M; Fan HY
    PLoS One; 2014; 9(3):e91770. PubMed ID: 24622501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
    Xia Y; Zhang YL; Yu C; Chang T; Fan HY
    PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.